EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of HBeAg anti-HBe chronic hepatitis B using thymosin-alpha1 and a combination of two nucleoside analogues Lamivudine and famciclovir



Treatment of HBeAg anti-HBe chronic hepatitis B using thymosin-alpha1 and a combination of two nucleoside analogues Lamivudine and famciclovir



Hepatology 34(4 Pt 2): 622A, October




(PDF 0-2 workdays service: $29.90)

Accession: 035980439

Download citation: RISBibTeXText



Related references

Treatment of chronic hepatitis B using thymosin alpha 1 and a combination of two nucleoside analogs, lamivudine and famciclovir. Hepatology 28(4 PART 2): 216A, 1998

Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir. Official Gazette of the United States Patent & Trademark Office Patents 1250(2), Sep 11, 2001

Treatment of chronic hepatitis B patients who are HBeAg negative and HBeAb positive with thymosin alpha-1 and lamivudine combination therapy. International Journal of Antimicrobial Agents 17(Supplement 1): S164, June, 2001

Lamivudine and famciclovir combination therapy with or without addition of IFN-alfa-2b for HBeAg positive chronic hepatitis B. Hepatology 36(4 Part 2): 630A, October, 2002

Lamivudine and famciclovir combination therapy with or without addition of interferon-alpha-2b for HBeAg-positive chronic hepatitis B: A pilot study. Scandinavian Journal of Infectious Diseases 34(7): 505-511, 2002

Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection. Clinical Infectious Diseases 29(6): 1575-1577, 1999

Effects of lamivudine and thymosin alpha1 combination therapy on patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 10(3): 218-219, 2002

Long-term outcomes of thymosin-alpha1 and interferon beta-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. Journal of Pharmaceutical Sciences 92(7): 1386-1395, 2003

Combination of lamivudine with thymosin alpha1 in treatment of duck hepatitis B. Zhejiang Da Xue Xue Bao. Yi Xue Ban 34(2): 121-125, 2005

Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. Journal of Gastroenterology and Hepatology 23(5): 729-735, 2008

Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. Journal of Viral Hepatitis 9(4): 280-287, 2002

Predictive value of ALT and HBV DNA levels in response to sequential combination treatment of lamivudine and interferon in HBeAg-/Anti-Hbe+ chronic hepatitis B. Journal of Hepatology 36(Supplement 1): 104, April, 2002

Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B. Journal of Viral Hepatitis 12(3): 262-268, 2005

A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B. Hepatology 38(4 Suppl 1): 724A-725A, October, 2003